Presentation is loading. Please wait.

Presentation is loading. Please wait.

Understanding the Pre-IDE Program: FDA Perspective

Published byArlene Jacobs Modified over 8 years ago

Similar presentations

Presentation on theme: "Understanding the Pre-IDE Program: FDA Perspective"— Presentation transcript:

1 Understanding the Pre-IDE Program: FDA Perspective
CAPT Stephen P. Rhodes, USPHS Director, IDE and HDE Programs Office of Device Evaluation AdvaMed AudioConference October 17, 2007 Stephen Rhodes, AdvaMed, October 2007

2 Collaboration with regulated industry are integral to our mission
Committed to communicating and interacting with our stakeholders ODE/OIVD have 400+ meetings/year Average 80 meetings per division: meetings/wk/division (not including teleconferences) FDAMA (1997): Early Collaboration meetings became regulation (Agreement, Determination meetings) AdvaMed October 17, PreIDEs

3 Why Pre-Submission Discussions?
Benefits (to sponsors and FDA) Design testing and development plans that will expedite review and approval Save money and time More collaborative approach Minimize surprises Cost (to sponsors and FDA) Time and effort Money AdvaMed October 17, PreIDEs

4 Advice may be requested at any of these points in premarket phase:
Prior to conducting “proof of concept” animal studies Preclinical Prior to expanding clinical trials from feasibility to pivotal phase Pre-PMA Day 100 PMA meetings Post-deficiency letter for 510(k) or PMA Appeal a final decision on a PMA or 510(k) or an IDE disapproval Agreement or determination meeting AdvaMed October 17, PreIDEs

5 Prior to Proof of Concept
Discuss concepts, broad outline of test plan, bench test methodologies (e.g., use of consensus standards, need for animal studies, need for clinical studies) Discuss possible regulatory pathways Discuss potential combination product issues Face-to-face meetings are usually not held at this stage (premature). AdvaMed October 17, PreIDEs

6 AdvaMed October 17, 2005 -- PreIDEs
Preclinical phase Prototype evaluated in preliminary animal models Proposed clinical application (possibly not specific patient population) and indication for use FDA feedback on: Bench testing plan – methods, standards Animal study protocols Feasibility study protocols Preliminary guidance on SR/NSR (need for IDE) Preliminary (non-binding) guidance on regulatory pathway Feedback dependent on focused questions PreIDE meetings/teleconferences encouraged at this stage AdvaMed October 17, PreIDEs

7 Prior to initiating pivotal trials
Feasibility studies completed (or nearly so) Device design finalized to extent possible Animal studies completed (or in follow-up) Pivotal trial protocol “fleshed out” (including 1º and 2º endpoints, duration, evaluation methods, statistical analysis) Specific indication for use (and patient population) determined AdvaMed October 17, PreIDEs

8 Prior to initiating pivotal trials (cont.)
FDA will give feedback on: Need for further bench/animal studies Need for pilot study prior to initiating pivotal study Proposed pivotal study protocol: endpoints, duration, evaluation, statistical analysis plan Proposed regulatory pathway Proposed indication for use Preliminary nonbinding feedback on expedited status, need for advisory panel meeting Feedback dependent on focused questions Meetings/teleconferences with FDA encouraged at this stage AdvaMed October 17, PreIDEs Stephen Rhodes, AdvaMed, October 2007

9 AdvaMed October 17, 2005 -- PreIDEs
Scheduling informal pre-IDE meetings (not determination or agreement meetings) Planning/scheduling may be done by project manager (usually 3-4 weeks after preIDE received) Complete pre-meeting package needed before meeting will be scheduled Divisions may have checklists/other guidelines for what is expected in pre-meeting package: Check! Expect meeting to be cancelled/postponed if extensive new information submitted after meeting scheduled AdvaMed October 17, PreIDEs

10 Pre-IDEs: What they are and what they are not
Tool to provide informal feedback on: Preclinical test plan Clinical/statistical test plan NSR/Exempt investigations OUS investigations NOT intended to be: A tool for negotiation An iterative process Modular review Review of data (“pre-510(k)”, “pre-PMA”) As in depth as an IDE or marketing application review Legally binding Method for dispute resolution AdvaMed October 17, PreIDEs

11 AdvaMed October 17, 2005 -- PreIDEs
Recommendations FDA is doing our homework before your meeting; please do yours! Think carefully about what you want to get from a meeting – are you ready to talk with FDA? If you must make changes to device or protocol after pre-IDE package has been submitted, be prepared to cancel and reschedule Manage your meeting time carefully Bring right people to discuss focused questions Ask for clarification AdvaMed October 17, PreIDEs

12 AdvaMed October 17, 2005 -- PreIDEs
Recommendations Do not expect FDA to: Make guarantees or binding commitments (unless it is a determination or agreement meeting) Approve study or clear/approve device at meeting Act as a consultant Give special treatment or favors Hold to informal feedback provided years ago – technology does not stay constant Have a series of meetings on the same topics – make the most of THIS meeting AdvaMed October 17, PreIDEs

13 AdvaMed October 17, 2005 -- PreIDEs
More Information October 10, 2007 Federal Register Notice: List of Guidance Documents under review in CDRH Pre-PMA and Pre-IDE Meetings CDRH Website: Device Advice AdvaMed October 17, PreIDEs Stephen Rhodes, AdvaMed, October 2007

Download ppt "Understanding the Pre-IDE Program: FDA Perspective"

Similar presentations

BME-IDEA Workshop, September 28, 2005

BME-IDEA Workshop, September 28, 2005
FDA Communications and Meetings

FDA Communications and Meetings
Participation Requirements for a Patient Representative.

Participation Requirements for a Patient Representative.
Determining the Regulatory Pathway to Market Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Strengthening the Medical Device Clinical Trial Enterprise

Strengthening the Medical Device Clinical Trial Enterprise
510k Submission Overview Myraqa, Inc. August 22, 2012.

510k Submission Overview Myraqa, Inc. August 22, 2012.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.

Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.

1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
FDA Pre-Submission Meetings for 510(k) Submissions

FDA Pre-Submission Meetings for 510(k) Submissions
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
CUMC IRB Investigator Meeting Special IND/IDE Considerations: Emergency Use of Investigational Product Compassionate Use & Emergency Research July 21,

CUMC IRB Investigator Meeting Special IND/IDE Considerations: Emergency Use of Investigational Product Compassionate Use & Emergency Research July 21,
Special Topics in IND Regulation

Special Topics in IND Regulation
MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.

MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.
Meetings with FDA Martha A. Feldman, RAC

Meetings with FDA Martha A. Feldman, RAC
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.

+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:

Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.
Associate Director for Review Management

Associate Director for Review Management
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

Similar presentations

Ads by Google